NCT06411080

UltraSound Evaluation of Fluid tOleRanCE for Acute Kidney Injury

UltraSound Evaluation of Fluid tOleRanCE for Acute Kidney Injury: A Pilot Randomized Controlled Trial
Centre hospitalier de l'Université de Montréal (CHUM)·ClinicalTrials.gov·diagnostic testNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Acute Kidney Injury
Drug/Device/Intervention
Ultrasound evaluation of fluid tolerance
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Location
Montréal, Canada
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2024
End date
Sep 01, 2026
Enrollment
80 participants
Primary outcome

Protocol adherence

Summary

Fluid expansion with isotonic crystalloids is a first-line intervention in the treatment of
 patients with acute kidney injury (AKI). While it is generally accepted that the timely
 correction of kidney hypoperfusion will minimize the extent of injury as well as potentially
 facilitate recovery, there are potential harms involved in indiscriminate administration of
 intravenous fluids. Although anticipating fluid tolerance is part of the clinical evaluation
 of a patient for whom intravenous fluid therapy is considered, it has been suggested that
 using Point-Of-Care ultrasound (POCUS) may enable the early identification of patients with a
 high-risk of congestive complications and guide clinical decisions with greater precision[1].
 However, it has not been shown that providing this information in the context of AKI result
 in a change in management or a prevention of complications.
 
 This single-center pilot randomized controlled trial aim to determine the feasibility of
 comparing a management including a POCUS evaluation of fluid tolerance to usual care in
 non-critically ill patients with AKI. In the intervention group, a POCUS evaluation will be
 performed and interpreted by experienced staff producing a report that will be presented to
 the attending care team. This assessment will be repeated 48-72 hours later. The primary aim
 of the study will be to establish the feasibility of this intervention. Secondary objectives
 will include determining the difference between the intervention arm and the control arm in
 relationship with fluid administration, diuretic use, evolution of kidney function, and
 intensification of care.

ICD-10 classifications
Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06411080
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06411080 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre hospitalier de l'Université de Montréal (CHUM) and is currently Not yet recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.